Skip to content
6-K

Foreign Interim / Material

Freeline Therapeutics Holdings plc

0000950170-23-042621

← back to feed
Filed
Aug 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2023 · Jun 30, 2023 65.14M sh
Shares Diluted Q2 2023 · Jun 30, 2022 53.59M sh
Capex Q2 2023 · Jun 30, 2023 $648K
Capex Q2 2023 · Jun 30, 2022 $939K
Operating Cash Flow Q2 2023 · Jun 30, 2023 −$35.72M
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$43.2M
Cash And Equivalents Q2 2023 · Jun 30, 2023 $38.8M
Cash And Equivalents Q2 2023 · Dec 31, 2022 $47.28M
Cash And Equivalents Q2 2023 · Jun 30, 2022 $90M
Stockholders Equity Q2 2023 · Jun 30, 2023 $42.02M
Stockholders Equity Q2 2023 · Dec 31, 2022 $52.41M
Current Liabilities Q2 2023 · Jun 30, 2023 $18.68M
Current Liabilities Q2 2023 · Dec 31, 2022 $30.97M
Total Liabilities Q2 2023 · Jun 30, 2023 $20.64M
Total Liabilities Q2 2023 · Dec 31, 2022 $34.23M
Current Assets Q2 2023 · Jun 30, 2023 $45.81M
Current Assets Q2 2023 · Dec 31, 2022 $67.63M
Total Assets Q2 2023 · Jun 30, 2023 $62.65M
Total Assets Q2 2023 · Dec 31, 2022 $86.64M
Eps Diluted Q2 2023 · Jun 30, 2023 −$0.23
Eps Diluted Q2 2023 · Jun 30, 2022 −$0.95
Eps Basic Q2 2023 · Jun 30, 2023 −$0.23
Eps Basic Q2 2023 · Jun 30, 2022 −$0.95
Sga Expense Q2 2023 · Jun 30, 2023 $17.58M
Sga Expense Q2 2023 · Jun 30, 2022 $16.28M
Rd Expense Q2 2023 · Jun 30, 2023 $19.72M
Rd Expense Q2 2023 · Jun 30, 2022 $38.79M
Net Income Q2 2023 · Jun 30, 2023 −$14.85M
Net Income Q2 2023 · Jun 30, 2022 −$51.08M
Operating Income Q2 2023 · Jun 30, 2023 −$35.73M
Operating Income Q2 2023 · Jun 30, 2022 −$55.06M
Revenue Q2 2023 · Jun 30, 2023 $617K